On August 21, Hang Seng Indexes Company announced the results of its quarterly index review for the period ending June 30, 2026. Notably, DIAGENS-B (02526) secured a dual inclusion, becoming a constituent of both the Hang Seng Composite Index and the Hang Seng Biotechnology Index. This makes it the sole company added to the Hang Seng Biotechnology Index during this adjustment cycle. According to the index provider's schedule, the changes to the Hang Seng Biotechnology Index will take effect after the market close on Friday, September 11, 2026, and will be officially implemented from Monday, September 14, 2026.
Founded in 2016, DIAGENS-B is a technology enterprise that leverages AI to revolutionize medical diagnostics, holding the top position in its sector. The company has developed iMedImage®, the world's first "core general-purpose brain" for medical imaging. This foundational large model operates at a scale of hundreds of billions of parameters, covering 19 medical imaging modalities and 26 clinical specialties. Building on this, it has established iMedLoop™, a globally leading "research and production acceleration platform" for medical imaging AI, which has accumulated a high-quality dataset of 28.95 million medical imaging records.
In the first half of 2026, the company reported total operating revenue of RMB 109 million, a 21.0% year-on-year increase, while maintaining a robust gross margin of 74.1%. Model service revenue, a key growth driver, surged 101.1% year-on-year to RMB 94.5 million, now accounting for 86.9% of total revenue.
The Hang Seng Biotechnology Index serves as a core benchmark for the biotechnology sector in the Hong Kong stock market, concentrating on representative innovative biotech firms. Its current constituents include major players like WuXi Biologics, BeiGene, Innovent Biologics, WuXi AppTec, and CSPC Pharmaceutical Group. This index is a critical reference for numerous passive index funds and institutional investors, meaning constituent changes directly influence the portfolio positioning of tracking capital.
In this quarterly review, DIAGENS-B's selection as the only new addition underscores the market's strong recognition of its technological prowess and standing in the AI-powered healthcare space. Furthermore, as a scarce pure-play AI4S (AI for Science) target in Hong Kong, DIAGENS-B has built a complete ecosystem spanning data to models, models to products, and products to clinical application. Amid the convergence of the AI4S industry wave and substantial southbound capital demand, this dual inclusion in the Hang Seng Index family is expected to significantly enhance the stock's liquidity and trading activity, unlocking considerable room for valuation growth.